# Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

> **NCT02825147** · PHASE2 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 40 (actual)

## Conditions studied

- Nasal Type Extranodal NK/T-Cell Lymphoma

## Interventions

- **DRUG:** Pegaspargase
- **DRUG:** Methotrexate
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT02825147
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-03
- **Final completion:** 2017-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825147, "Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02825147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*